4Strijkers GJ,Kluza E,Van Tilborg GA,et ah Paramagnet-ic and fluorescent liposomes for target-specific imagingand therapy of tumor angiogenesis[J]. Angiogenesis, 2010,13(2):161.
5Zuo J,Gong T, Sun X^et al. Multivesicular liposomes forthe sustained release of thymopentin: stability, pharmaco-kinetics and pharmacodynamics[J]. Pharmazie,2012, 67(6):507.
6Kim S,Turker MS, Chi EY,et al. Prepartion of multivesic-ular liposomes[J]. Biochim Biophys Acta, 1983,728 (3):339.
7Kim S,Sankaram MB. Multivesicular liposomes with con-trolled release of encapsulated biologically active sub-5to.ce5:US,6132766[P].2000-10-17.
8Mantripragada S. A lipid based depot (DepoFoam technol-ogy) for sustained release drug delivery[J], Prog Lipid紅2002,41(5):392.
9Dominguez AR,Hidalgo DO,Garrido RV, et al. Liposo-mal cytarabine (DepoCyt.) for the treatment of neoplas-tic meningitis [J]. Clin Transl Oncol,2005,7(6): 232.
10Angst MS,Drover DR. Pharmacology of drugs formulatedwith DepoFoam: a sustained release drug delivery systemfor parenteral administration using multivesicular lipo-some technology [J]. Clin Pharmacokinet,2006,45(12):1 153.
